Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CannaMedical Indica is a branded line of **dried medical cannabis flower** products developed and distributed by Cannamedical Pharma for the German medical cannabis market. It is a **botanical cannabis drug product** composed of indica-dominant *Cannabis sativa L.* flower with strain-dependent cannabinoid content, typically characterized by relatively high **tetrahydrocannabinol** levels and low **cannabidiol** content, plus naturally occurring terpenes such as limonene, myrcene, and beta-caryophyllene. Its pharmacology is driven primarily by THC-mediated activation of the endocannabinoid system, especially cannabinoid receptors in the central and peripheral nervous system, producing relaxing, calming, analgesic, appetite-stimulating, and sleep-promoting effects. The product line is used in medical practice for symptoms and conditions such as chronic pain, sleep disturbance, stress, anxiety, inflammation, and appetite loss, and is intended particularly for evening use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CannaMedical Indica.